Avantor Announces Emmanuel Ligner as Next President and CEO
Avantor (NYSE:AVTR) has appointed Emmanuel Ligner as its new President and Chief Executive Officer, effective August 18, 2025. Ligner, who brings over 30 years of life sciences industry experience, will succeed Michael Stubblefield.
Ligner's extensive background includes 12 years at GE Life Sciences in global leadership positions, serving as President and CEO of Cytiva where he integrated Pall Life Sciences, and most recently as CEO of Cerba HealthCare. The appointment aims to drive competitive growth in both Lab Solutions and Bioscience Production divisions.
Avantor (NYSE:AVTR) ha nominato Emmanuel Ligner come nuovo Presidente e Amministratore Delegato, con decorrenza dal 18 agosto 2025. Ligner, che vanta oltre 30 anni di esperienza nel settore delle scienze della vita, succederà a Michael Stubblefield.
Il suo ampio percorso professionale comprende 12 anni in GE Life Sciences in ruoli di leadership globale, con la carica di Presidente e CEO di Cytiva, dove ha gestito l'integrazione di Pall Life Sciences, e più recentemente come CEO di Cerba HealthCare. La nomina punta a stimolare una crescita competitiva sia nella divisione Lab Solutions che in quella Bioscience Production.
Avantor (NYSE:AVTR) ha nombrado a Emmanuel Ligner como su nuevo Presidente y Director Ejecutivo, con efecto a partir del 18 de agosto de 2025. Ligner, con más de 30 años de experiencia en la industria de ciencias de la vida, sucederá a Michael Stubblefield.
Su amplia experiencia incluye 12 años en GE Life Sciences en puestos de liderazgo global, desempeñándose como Presidente y CEO de Cytiva, donde integró Pall Life Sciences, y más recientemente como CEO de Cerba HealthCare. El nombramiento busca impulsar un crecimiento competitivo en las divisiones de Lab Solutions y Bioscience Production.
Avantor (NYSE:AVTR)� 2025� 8� 18일부� Emmanuel Ligner� 새로� 사장 � 최고경영�(CEO)� 임명했습니다. Ligner� 30� 이상� 생명과학 산업 경험� 보유하고 있으�, Michael Stubblefield� 후임입니�.
Ligner� 글로벌 리더� 직책에서 GE Life Sciences에서 12� 근무했으�, Pall Life Sciences� 통합� Cytiva� 사장 � CEO� 재직했고, 최근에 Cerba HealthCare� CEO� 역임했습니다. 이번 임명은 Lab Solutions와 Bioscience Production 부문의 경쟁� 있 성장� 촉진하 것을 목표� 합니�.
Avantor (NYSE:AVTR) a nommé Emmanuel Ligner en tant que nouveau Président et Directeur Général, à compter du 18 août 2025. Ligner, qui possède plus de 30 ans d'expérience dans l'industrie des sciences de la vie, succédera à Michael Stubblefield.
Son parcours étendu comprend 12 ans chez GE Life Sciences à des postes de direction mondiale, en tant que Président et CEO de Cytiva où il a intégré Pall Life Sciences, et plus récemment en tant que CEO de Cerba HealthCare. Cette nomination vise à stimuler une croissance compétitive dans les divisions Lab Solutions et Bioscience Production.
Avantor (NYSE:AVTR) hat Emmanuel Ligner mit Wirkung zum 18. August 2025 zum neuen Präsidenten und Chief Executive Officer ernannt. Ligner bringt über 30 Jahre Erfahrung in der Life-Sciences-Branche mit und wird Michael Stubblefield nachfolgen.
Ligners umfassender Hintergrund umfasst 12 Jahre bei GE Life Sciences in globalen Führungspositionen, darunter als Präsident und CEO von Cytiva, wo er Pall Life Sciences integrierte, sowie zuletzt als CEO von Cerba HealthCare. Die Ernennung zielt darauf ab, das wettbewerbsfähige Wachstum in den Bereichen Lab Solutions und Bioscience Production voranzutreiben.
- Appointment of highly experienced executive with over 30 years in life sciences industry
- Strong leadership track record in similar companies (GE Life Sciences, Cytiva)
- Proven experience in commercial growth and business integration
- Transition period could create temporary operational uncertainty
- Change in strategic direction might impact ongoing initiatives
Insights
Avantor's appointment of seasoned life sciences executive Emmanuel Ligner as CEO represents a strategic leadership transition focused on growth acceleration.
Avantor's appointment of Emmanuel Ligner as President and CEO marks a significant leadership transition for this life sciences and advanced technology supplier. Ligner's selection appears strategically aligned with Avantor's growth ambitions, particularly given his extensive 30-year industry experience and proven track record in commercial growth leadership.
Most notably, Ligner's background includes successfully launching and building Cytiva following its divestiture from GE Life Sciences to Danaher, demonstrating his capability in managing complex organizational transitions and integrations. His experience integrating Pall Life Sciences into Cytiva is particularly relevant as it shows competence in consolidating complementary business units � a critical skill for driving efficiency and growth at Avantor.
The Board's explicit mention of delivering "competitive growth and value in both Lab Solutions and Bioscience Production" signals that Avantor is looking to accelerate performance across its core business segments. This leadership change appears to be a deliberate move to bring in expertise specifically tailored to Avantor's current portfolio and market positioning.
This transition follows what appears to be a planned succession process, as indicated by the reference to the previous announcement of Michael Stubblefield stepping down. Such orderly transitions typically minimize operational disruption. Ligner's comments about capitalizing on market opportunities suggest he may implement strategic changes to enhance Avantor's competitive positioning and shareholder value creation, though specific strategic initiatives remain to be articulated.
Seasoned Executive with Proven Track Record of Value Creation in Life Sciences
Mr. Ligner succeeds Michael Stubblefield, who will, as previously announced, step down from his role as Director, President and Chief Executive Officer upon Mr. Ligner's appointment.
Mr. Ligner brings more than 30 years of experience and an outstanding track record of driving growth and value creation in the life sciences industry. During his 12 years at GE Life Sciences, Mr. Ligner held several global leadership positions with a focus on commercial growth, culminating in his appointment as President and CEO. Following the sale of the biopharma business at GE Life Sciences to Danaher Corporation, Mr. Ligner led the launch of Cytiva and spent four years building the business into a powerful standalone life sciences brand including the integration of Pall Life Sciences. He most recently served as Chief Executive Officer of Cerba HealthCare.
"Emmanuel is a proven CEO and leader with extensive experience driving commercial growth and building high-performing, empowered teams at large-scale global life sciences organizations," said Jonathan Peacock, Chairman of the Board of Directors. "The Board is confident Emmanuel is the right person to lead Avantor in its next chapter to deliver competitive growth and value in both Lab Solutions and Bioscience Production."
Mr. Ligner said, "I have long admired Avantor as an industry leader with an attractive portfolio, global supply chain and diverse customer base. I believe this company has tremendous potential and I look forward to working closely with our Board, leadership team and the thousands of talented associates around the world to capitalize on market opportunities and create value for shareholders."
About Emmanuel Ligner
Mr. Ligner most recently served as Chief Executive Officer at Cerba HealthCare. Prior to that, Mr. Ligner was President and Chief Executive Officer of Cytiva, a part of the Danaher Corporation. Before Cytiva, he held several leadership positions in
Mr. Ligner holds an MA of Commerce from Université e de
Second Quarter 2025 Results and Conference Call
As previously announced, Avantor will hold a conference call to discuss its second quarter 2025 financial results on Friday, August 1, 2025, at 8:00 a.m. Eastern Time.
About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visitavantorsciences.comand find us onLinkedIn,ԻFacebook.
Forward-Looking and Cautionary Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, including our cost transformation initiative, objectives, future performance and business. These statements may be preceded by, followed by or include the words "aim," "anticipate," "assumption," "believe," "continue," "estimate," "expect," "forecast," "goal," "guidance," "intend," "likely," "long-term," "near-term," "objective," "opportunity," "outlook," "plan," "potential," "project," "projection," "prospects," "seek," "target," "trend," "can," "could," "may," "should," "would," "will," the negatives thereof and other words and terms of similar meaning.
Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in "Risk Factors" in our most recent Annual Report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC.
All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.
Investor Relations Contact
Allison Hosak
Senior Vice President, Global Communications
Avantor
908-329-7281
[email protected]
Global Media Contact
Eric Van Zanten
Head of External Communications
Avantor
610-529-6219
[email protected]
View original content to download multimedia:
SOURCE Avantor and Financial News